Chicken Pox Info
Tuesday, January 31, 2023
  • Home
  • Chickenpox
  • Monkeypox
  • Cowpox
  • Goatpox
  • Horsepox
  • Sheeppox
  • Squirrelpox
No Result
View All Result
  • Home
  • Chickenpox
  • Monkeypox
  • Cowpox
  • Goatpox
  • Horsepox
  • Sheeppox
  • Squirrelpox
No Result
View All Result
Chicken Pox Info
No Result
View All Result
Home Monkeypox

Real-time forecasting the trajectory of monkeypox outbreaks at the national and global levels, July–October 2022 | BMC Medicine

Chickenpox Info by Chickenpox Info
January 16, 2023
in Monkeypox
0
Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation | BMC Medicine
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Microbix Biosystems Launches QAP to Support “Monkeypox” Testing

Microbix Launches QAP to Support “Monkeypox” Testing


Data

We obtained weekly updates of the daily confirmed monkeypox cases by reporting date from publicly available sources by the CDC and the Our World in Data (OWID) GitHub repository [24, 25]. At the global level and for countries that have reported the great majority of the cases, including Brazil, Canada, England, France, Germany, Spain, and the USA, we retrieved daily case series from the GitHub Our World in Data (OWID) repository [8, 25]. We reported forecasts based on CDC and OWID team data for the USA. The CDC and OWID data sources define a confirmed case as a person with a laboratory-confirmed case of monkeypox [26, 27]. Data were downloaded every Wednesday evening from the CDC and every Friday afternoon from the GitHub Our World in Data (OWID) repository from the week of July 28th, 2022, through the week of October 13th, 2022. For the week of July 28th, 2022, data posted by the OWID team on August 9th, 2022, was used to produce the forecast as it was the earliest data available.

The n-sub-epidemic modeling framework

A detailed description of our modeling framework is given in ref. [19]. In this n-sub-epidemic modeling framework, epidemic trajectories are modeled as the aggregation of overlapping and asynchronous sub-epidemics. A sub-epidemic follows the 3-parameter generalized-logistic growth model (GLM), which has displayed competitive performance [28,29,30]. This model is given by the following differential equation:

$$\frac{dC(t)}{dt}={C}^{\prime }(t)=r{C}^p(t)\left(1-\frac{C(t)}{K_0}\right),$$

where C(t) denotes the cumulative number of cases at time t and \(\frac{dC(t)}{dt}\) describes the curve of daily cases over time t. The parameter r is positive, denoting the growth rate per unit of time, K0 is the final outbreak size, and p ∈ [0, 1] is the “scaling of growth” parameter which allows the model to capture early sub-exponential and exponential growth patterns. If =0 , this equation describes a constant number of new cases over time, while p = 1 indicates that the early growth phase is exponential. Intermediate values of p (0 <p < 1) describe early sub-exponential (e.g., polynomial) growth dynamics.

An n-sub-epidemic trajectory comprises n overlapping sub-epidemics and is given by the following system of coupled differential equations:

$$\frac{d{C}_i(t)}{dt}={C_i}^{\prime }(t)={A}_i(t){r}_i{C_i}^{p_i}(t)\left(1-\frac{C_i(t)}{{K_0}_i}\right),$$

where Ci(t) tracks the cumulative number of cases for sub-epidemic i, and the parameters that characterize the shape of the ith sub-epidemic are given by (ri, pi, K0i), for i = 1, …, n. Thus, the 1-sub-epidemic model is equivalent to the generalized growth model described above. When n > 1, we model the onset timing of the (i + 1)th sub-epidemic, where (i + 1) ≤ n, by employing an indicator variable given by Ai(t) so that the (i + 1)th sub-epidemic is triggered when the cumulative curve of the ith sub-epidemic exceeds Cthr.

The (i + 1)th sub-epidemic is only triggered when Cthr ≤ K0i. Then, we have:

$${A}_i(t)=\left\{\begin{array}{c}1,{C}_{i-1}(t)>{C}_{thr}\\ {}\ \\ {}0, Otherwise\end{array}\right.i=2,\dots n,$$

where A1(t) = 1 for the first sub-epidemic. Hence, the total number of parameters that are needed to model an n-sub-epidemic trajectory is given by 3n + 1. The initial number of cases is given by C1(0) = I0, where I0is the initial number of cases in the observed data. The cumulative curve of the n-sub-epidemic trajectory is given by:

$$C_{tot}(t)=\sum_{i=1}^nC_i(t).$$

Hence, this modeling framework is suitable for diverse epidemic patterns including those characterized by multiple peaks.

Parameter estimation for the n-sub-epidemic model

The time series of new weekly monkeypox cases are denoted by:

\({y}_{t_j=}{y}_{t_1,}{y}_{t_2},\dots, {y}_{t_{n_d}}\)where j = 1, 2, …, nd

Here, tj are the time points for the time series data, nd is the number of observations. Using these case series, we estimate a total of 3n + 1 model parameters, namely Θ = (Cthr, r1, p1, K01, …, rn, pn, K0n). Let f(t, Θ) denote the expected curve of new monkeypox cases of the epidemic’s trajectory. We can estimate model parameters by fitting the model solution to the observed data via nonlinear least squares [31] or via maximum likelihood estimation assuming a specific error structure [32]. For nonlinear least squares, this is achieved by searching for the set of parameters \(\hat{\varTheta}\)that minimizes the sum of squared differences between the observed data \({y}_{t_j=}{y}_{t_1,}{y}_{t_2}\dots ..{y}_{t_{n_d}}\)and the model mean f(t, Θ). That is, Θ = (Cthr, r1, p1, K01, …, rn, pn, K0n) is estimated by \(\hat{\varTheta}=\mathit{\arg}\mathit{\min }\ {\sum}_{j=1}^{n_d}{\left(f\left({t}_j,\varTheta \right)-{y}_{t_j}\right)}^2\).

We quantify parameter uncertainty using a bootstrapping approach described in [33], which allows the computation of standard errors and related statistics in the absence of closed-form solutions. To that end, we use the best-fit model \(f\left(t,\hat{\varTheta}\right)\) to generate B-times replicated simulated datasets of size nd, where the observation at time tjis sampled from a normal distribution with mean \(f\left({t}_j,\hat{\varTheta}\right)\) and variance \(\frac{\sum_{j=1}^{n_d}{\left(f\left({t}_j,\hat{\varTheta}\right)-{y}_{t_j}\right)}^2}{n_d-\left(3n+1\right)}\). Then, we refit the model to each B simulated dataset to re-estimate each parameter. The new parameter estimates for each realization are denoted by \({\hat{\varTheta}}_b\)where b = 1, 2, …, B. Using the sets of re-estimated parameters \(\left({\hat{\varTheta}}_b\right),\) the empirical distribution of each estimate can be characterized, and the resulting uncertainty around the model fit can similarly be obtained from \(f\left(t,{\hat{\varTheta}}_1\right),\)\(f\left(t,{\hat{\varTheta}}_2\right),\dots, f\left(t,{\hat{\varTheta}}_B\right)\). We run the calibrated model forward in time to generate short-term forecasts with quantified uncertainty.

Selecting the top-ranked sub-epidemic models

We used the AICc values of the set of best fit models based on one and two subepidemics to select the top-ranked sub-epidemic models. We ranked the models from best to worst according to their AICc values, which is given by [34, 35]:

$${AIC}_c={n}_d\mathit{\log}(SSE)+2m+\frac{2m\left(m+1\right)}{n_d-m-1}$$

where \(SSE={\sum}_{j=1}^{n_d}{\left(f\left({t}_j,\hat{\varTheta}\right)-{y}_{t_j}\right)}^2\), m = 3n + 1 is the number of model parameters, and nd is the number of data points. Parameters from the above formula for AICc are estimated from the nonlinear least-squares fit, which implicitly assumes normal distribution for error.

Constructing ensemble n-sub-epidemic models

We generate ensemble models from the weighted combination of the highest-ranking sub-epidemic models as deemed by the \({AIC}_{c_i}\) for the ith ranked model where \({AIC}_{c_1}\le \dots \le {AIC}_{c_I}\) and i = 1, …, I. An ensemble derived from the top-ranking I models is denoted by Ensemble(I). Thus, Ensemble (2) refers to the ensemble model generated from the weighted combination of the top-ranking 2 sub-epidemic models. We compute the weight wi for the ith model, i = 1, … , I, where ∑wi = 1 as follows:

\(w_i=\frac{l_i}{l_1+l_2+\dots+l_I}\;for\;all\;i=1,2,\dots,I,\)

where li is the relative likelihood of model i, which is given by \({l}_i={e}^{\left(\left({AIC}_{min}-{AIC}_i\right)/2\right)}\) [36], and hence wI ≤ … ≤ w1 . The prediction intervals based on the ensemble model can be obtained using a bootstrap approach similar as before. We employed the first-ranked and the second-ranked models to derive the ensemble forecasts. AICc values of the top models for the most recent forecast can be found in figure 1s (Additional file 1) [24, 25].

Forecasting strategy

Using a 10-week calibration period for each model, we have conducted 324 real-time weekly sequential 4-week ahead forecasts across studied areas and models (week of July 28th–week of October 13th, 2022) thus far. At the national and global levels, we also report forecasting performance metrics for 8 sequential forecasting periods covering the weeks of July 28th, 2022, through September 15, 2022, for which data was available to assess the 4-week ahead forecasts. We also compare the predicted cumulative cases for the 4-week forecasts across models for a given setting. Cumulative cases for a given model were calculated as the sum of median number of new cases predicted during the 4-week forecast. Forecasts were evaluated using data reported during the week of October 13th, 2022.

Performance metrics

Across geographic areas, we assessed the quality of our model fit and performance of the short-term forecasts for each model by using four standard performance metrics: the mean squared error (MSE) [37], the mean absolute error (MAE) [38], the coverage of the 95% prediction interval (PI) [37], and the weighted interval score (WIS) [20, 39]. While MSE and MAE assess the average deviations of the mean model fit to the observed data, the coverage of the 95% PI and the weighted interval score consider the uncertainty of the forecasts.

ShareTweetPin
Chickenpox Info

Chickenpox Info

Related Posts

Thermo Fisher Scientific's Monkeypox Test Receives Emergency Use Authorization From US FDA

Microbix Biosystems Launches QAP to Support “Monkeypox” Testing

by Chickenpox Info
January 30, 2023
0

MT Newswires 2023 All news about MICROBIX BIOSYSTEMS INC. Sales 2023 16,6 M - - Net...

Microbix Launches QAP to Support “Monkeypox” Testing

Microbix Launches QAP to Support “Monkeypox” Testing

by Chickenpox Info
January 30, 2023
0

MISSISSAUGA, Ontario, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer,...

Ghana records 116 cases of Monkey Pox and four deaths

Ghana records 116 cases of Monkey Pox and four deaths

by Chickenpox Info
January 29, 2023
0

Ghana recorded four deaths and 116 confirmed cases of the Monkeypox disease in 2022, in 14 out of the 16...

Ghana records 116 cases of Monkey Pox and four deaths

Ghana records 116 cases of Monkey Pox with four deaths

by Chickenpox Info
January 29, 2023
0

On Jan 29, 2023 Last updated Jan 30, 2023 Ghana recorded four deaths and 116 confirmed cases of the...

Consider 2 Safety Issues When Treating, Vaccinating for Monkeypox

Consider 2 Safety Issues When Treating, Vaccinating for Monkeypox

by Chickenpox Info
January 27, 2023
0

Pharmacists should consider 2 critical safety issues when treating or vaccinating patients for monkeypox.First, it is vital to understand that...

Next Post
J&K declared as Lumpy Skin Disease free – The Dispatch

J&K declared as Lumpy Skin Disease free – The Dispatch

Squirrelpox outbreak prompts concern for red squirrels

Squirrelpox outbreak prompts concern for red squirrels

RECOMMENDED

North Goa extends ban on cattle transportation: Lumpy skin disease

Lumpy skin disease: North Goa extends ban on cattle transportation

January 31, 2023
Lumpy skin disease: North Goa extends ban on cattle transportation from other states by 2 months

North Goa extends ban on cattle transportation from other states by 2 months

January 31, 2023

MOST VIEWED

  • Can you catch chickenpox twice? How contagious is virus and symptoms explained

    How long does chickenpox last? When do symptoms go away, how long is it contagious – and is there treatment

    0 shares
    Share 0 Tweet 0
  • TikTok craze of using calamine lotion as makeup causing chickenpox treatment shortages, pharmacy warns

    0 shares
    Share 0 Tweet 0
  • What happened to monkeypox? Answers to your most pressing questions.

    0 shares
    Share 0 Tweet 0
  • Research finds link between chickenpox and Alzheimer’s

    0 shares
    Share 0 Tweet 0
  • Monkeypox Virus Can Survive on Surface of Household Objects: Report

    0 shares
    Share 0 Tweet 0

Chicken Pox Info

Welcome to Chicken Pox Info, where you will get all the latest news about all the different pox diseases, to stay up to date, and to protect yourself.

CATEGORY

  • Chickenpox
  • Cowpox
  • Goatpox
  • Horsepox
  • Monkeypox
  • Sheeppox
  • Squirrelpox

Site Links

  • Home
  • About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions

Latest News

  • Lumpy skin disease: North Goa extends ban on cattle transportation
  • North Goa extends ban on cattle transportation from other states by 2 months
  • Lumpy skin disease: North Goa extends ban on cattle transportation from other states by 2 months

Copyright © 2022 Chickenpoxinfo.com | All Rights Reserved.

No Result
View All Result
  • Home
  • Chickenpox
  • Monkeypox
  • Cowpox
  • Goatpox
  • Horsepox
  • Sheeppox
  • Squirrelpox

Copyright © 2022 Chickenpoxinfo.com | All Rights Reserved.

What Are Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT